DK1654353T3 - Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf - Google Patents

Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf

Info

Publication number
DK1654353T3
DK1654353T3 DK04764266.5T DK04764266T DK1654353T3 DK 1654353 T3 DK1654353 T3 DK 1654353T3 DK 04764266 T DK04764266 T DK 04764266T DK 1654353 T3 DK1654353 T3 DK 1654353T3
Authority
DK
Denmark
Prior art keywords
dsm
applications
cell lines
tumor cell
acc2605
Prior art date
Application number
DK04764266.5T
Other languages
English (en)
Inventor
Steffen Goletz
Hans Baumeister
Marion Schlangstedt
Ute Schoeber
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Application granted granted Critical
Publication of DK1654353T3 publication Critical patent/DK1654353T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK04764266.5T 2003-08-18 2004-08-18 Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf DK1654353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03018576 2003-08-18
PCT/EP2004/009281 WO2005017130A2 (en) 2003-08-18 2004-08-18 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof

Publications (1)

Publication Number Publication Date
DK1654353T3 true DK1654353T3 (da) 2013-08-26

Family

ID=34178385

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04764266.5T DK1654353T3 (da) 2003-08-18 2004-08-18 Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf

Country Status (9)

Country Link
US (2) US8017388B2 (da)
EP (1) EP1654353B1 (da)
CY (1) CY1114643T1 (da)
DK (1) DK1654353T3 (da)
ES (1) ES2425475T3 (da)
PL (1) PL1654353T3 (da)
PT (1) PT1654353E (da)
SI (1) SI1654353T1 (da)
WO (1) WO2005017130A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482720T1 (de) * 2002-08-16 2010-10-15 Glycotope Gmbh Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
CN103627670B (zh) * 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
EP1900750A1 (en) * 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
EP1911766A1 (en) * 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
NZ575974A (en) 2006-09-10 2012-03-30 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US20130130317A1 (en) 2010-08-02 2013-05-23 Kyowa Hakko Kirin Co., Ltd Method for producing substance
DK2603528T3 (da) 2010-08-10 2016-11-28 Glycotope Gmbh Fab-glycosylerede antistoffer
ES2710543T3 (es) 2010-12-27 2019-04-25 Kyowa Hakko Kirin Co Ltd Método para preparar una disolución acuosa que contiene medio de cultivo y agente quelante
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
CN108588030B (zh) * 2018-03-30 2020-07-14 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
SI3794042T1 (sl) 2018-05-18 2024-07-31 Daiichi Sankyo Co., Ltd. Konjugat protitelesa anti-MUC1-exatecan in citotoksično sredstvo
WO2020091041A1 (ja) 2018-11-02 2020-05-07 協和キリン株式会社 液体培地の調製方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
WO1999026663A2 (en) * 1997-11-20 1999-06-03 Vical, Inc. Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6984384B1 (en) * 1999-09-30 2006-01-10 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
WO2004009632A2 (de) 2002-07-22 2004-01-29 Nemod Immuntherapie Ag Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
ATE482720T1 (de) * 2002-08-16 2010-10-15 Glycotope Gmbh Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf

Also Published As

Publication number Publication date
US20110319590A1 (en) 2011-12-29
SI1654353T1 (sl) 2013-09-30
WO2005017130A2 (en) 2005-02-24
ES2425475T3 (es) 2013-10-15
PT1654353E (pt) 2013-08-23
US8283161B2 (en) 2012-10-09
WO2005017130A3 (en) 2005-06-23
EP1654353A2 (en) 2006-05-10
US20060292129A1 (en) 2006-12-28
PL1654353T3 (pl) 2013-11-29
CY1114643T1 (el) 2016-10-05
US8017388B2 (en) 2011-09-13
EP1654353B1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
DK3246399T3 (da) Alfavirus-partikler og fremgangsmåder til fremstilling
DK1506288T3 (da) Aktiveringsinduceret deaminase (aid)
DK1591446T3 (da) Thienopyrimidinforbindelser og anvendelse deraf.
DK1478648T3 (da) Phosphorholdige forbindelser og anvendelser deraf
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DE60319430D1 (de) R- und fgfr-inhibitoren
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
IS8457A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
DK1641822T3 (da) Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
NO20021341D0 (no) Autentisering og tilgangsstyring
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
IS8453A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
FI20031133A0 (fi) Sulkimella varustettu liitin
DE60324067D1 (de) Informationsverarbeitungsgerät und -vorrichtung
DK1654353T3 (da) Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
AU2003250498A8 (en) Processing application data
IS7594A (is) Laxófoxifen tafla og húðun hennar
DK1554250T3 (da) Hidtil ukendt lactamer og anvendelser deraf
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
IS7783A (is) Flóð og fjöru-ker
IS8455A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
IS8489A (is) Umritunarstillar og aðferðir þeirra
DK1359458T3 (da) Brillestel og hængselsenhed til anvendelse deri
DK1506291T3 (da) Nye phospholipaser og anvendelser deraf